Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT02777476

Clinical Performance of B-Lite® Light Weight Breast Implant

This is a post-marketing study for B-Lite® implants that carry the EC certificate for marketing in Europe and AMAR certificate for marketing in Israel. To date, thousands of implants have already been implanted in women. The study is open for primary augmentation patients only. All surgeries will be performed as per standard practice at the given study site. No parallel surgical procedures will be performed at the same session.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Age range

18 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

ETHIANUM, Heidelberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Genetic women between the ages of 18 and 60 seeking primary breast augmentation
  • Patient is eligible to undergo MRI (i.e., no implanted metal or metal devices, no history of severe claustrophobia)
  • Patient provides signed informed consent
  • Patient agrees to comply with the study protocol and complete all required follow up visits, including to undergo MRI
  • Patient agrees to return the device to the Sponsor should the implant have to be explanted
  • The patient has realistic expectations of surgical results after discussion with investigator and is an acceptable candidate for breast augmentation.

Exclusion criteria

  • Patients with active infection anywhere in their body
  • Patient is pregnant or nursing at the time of recruitment, or has been in the 6 months preceding recruitment date, or not willing to use reliable means of contraception during the first year after surgery
  • Patient was implanted with any silicone implant other than breast implants (e.g., silicone artificial joints or facial implants)
  • Patient breast tissue is clinically incompatible for the procedure (e.g., tissue damage resulting from radiation, insufficient tissue coverage or compromised vascularity)
  • Patient has a condition, or is under treatment for any condition, which, in the opinion of the investigator and/or consulting physician(s), may constitute an unwarranted surgical risk (e.g., unstable cardiac or pulmonary problems, possible allergies and/or extraordinary immune response to implant)
  • The patient has a history of mental instability and/or history of pharmaceutical psychiatric treatment
  • Patient unable to understand the scope of the study and/or surgery
  • The patient has any disease, including uncontrolled diabetes (e.g., HbA1c > 8%), that is clinically known to impact wound healing ability
  • Patient has existing costal injuries
  • Patient has abscesses, malignant tumors (cancer or recurrent metastases), clinically relevant cysts or advanced fibrotic disease or patient with BIRAD ≥3
  • Are not willing to undergo further surgery for revision, if medically required
  • The patient has a confirmed rheumatic disease or syndrome (e.g., SLE, Sjogren's syndrome, scleroderma, polymyositis or any connective tissue disorder, rheumatoid arthritis, crystalline arthritis, infectious arthritis, spondyloarthropathies, any other inflammatory arthritis, fibromyalgia or chronic fatigue syndrome)
  • The patient has a severe breast and upper trunk deformity
  • The patient participated in an investigational trial within 90 days of enrollment
  • The patient has undergone an invasive medical procedure within 90 days of enrollment.
  • Aesthetic addiction, drug abuse, alcohol abuse

Treatment and study plan

B-Lite- Light Weight Breast Implants

Device

Primary outcomes

  1. Changes in breast size measurements

    Time frame: 3 years

  2. Changes in bra size measurements

    Time frame: 3 years

Sponsors and collaborators

Lead sponsor

G&G Biotechnology Ltd.

Industry

Registry information

Important dates

Study start
2016
Primary completion
2026
Study completion
2028
First posted
May 19, 2016
Registry last updated
Sep 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.